Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.

Hair follicle regeneration needs special conditions and young cells.

Skin problems in COVID-19 patients are rare and may be due to the body's complex immune response or blood clotting issues.

COVID-19 can cause various skin lesions, which may result from the virus and immune response, and are not directly linked to illness severity.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

Hidradenitis suppurativa is caused by genetic factors, inflammation, bacteria, hormones, and lifestyle factors like obesity and smoking.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Treatment with plasma rich in growth factors improved hair density and thickness for hair loss patients.

Cancer can hijack the body's cell repair system to promote tumor growth, and targeting this process may improve cancer treatments.

Tiny needles with valproic acid can effectively regrow hair.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Tissue-resident memory T cells can protect against infections and cancer but may also contribute to autoimmune diseases.

The document concludes that for hair and feather growth, it's better to target the environment around stem cells than the cells themselves.

Blocking the CXCR3 receptor reduces T cell accumulation in the skin and prevents hair loss in mice.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

The document concludes that the skin's immune system is complex, involving interactions with hair follicles, nerves, and microbes, and can protect or cause disease, offering targets for new treatments.

Ginseng and its compounds may help hair growth and prevent hair loss, but more human trials are needed to confirm this.

The conclusion is that acne, alopecia, and hyperhidrosis are common skin issues with various treatments available, and accurate diagnosis is key for effective management.

The document concludes that understanding and treating hair loss requires recognizing its various types and using appropriate diagnostic tools and treatments.

New alopecia treatments aim for better results and fewer side effects.

Tofacitinib is effective and safe for treating severe hair loss in Korean patients.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

Tumor suppressors help control inflammation in cancer and restoring their function could lead to new treatments.

Apremilast was not effective in treating moderate-to-severe alopecia areata.

Some alternative treatments for hair loss might work, but more research is needed.

Bimatoprost is promising for treating some types of hair loss but needs more testing for androgenetic alopecia.

Androgens may influence T cells, contributing to higher autoimmune liver disease risk in women.